Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Feb 10, 2017, 06:50 ET Immunomedics Enters into Exclusive Global Licensing Agreement with Seattle Genetics for Sacituzumab Govitecan (IMMU-132) with Potential Payments of up to Approximately $2 Billion, Plus Royalties

Immunomedics, Inc. (NASDAQ: IMMU) ("Immunomedics") today announced that it has entered into an exclusive global licensing agreement with Seattle...


Feb 09, 2017, 12:00 ET El gen de una nueva forma de la distrofia muscular es encontrado por los investigadores financiados por March of Dimes

Un misterio médico para los niños con una variedad extraña de síntomas ha sido desbloqueado por investigadores, financiados en parte por March of...


Feb 09, 2017, 12:00 ET Gene for a New Form of Muscular Dystrophy Found by Researchers Funded by March of Dimes

A medical mystery for children with an unusual array of symptoms has been unlocked by researchers funded in part by the March of Dimes, who have...


Feb 09, 2017, 09:13 ET Sidra Lead Team of Experts Successfully Complete Complex Procedure in a Middle East First

Remarkable series of surgeries over a two-year period saves young baby from life threatening OEIS Syndrome A multidisciplinary team made up of...


Feb 09, 2017, 09:01 ET VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS)

VM BioPharma, the United States division of ViroMed Co., Ltd. in Seoul, South Korea (KOSDAQ: 084990), today announced that the scientific journal,...


Feb 09, 2017, 09:00 ET Multiplexed Analysis of ALK, ROS1, and RET Rearrangements in Lung Cancer Enabled by the MassARRAY® System

Agena Bioscience today announced a comparative study published in Scientific Reports highlighting the use of its mass spec-based platform for...


Feb 09, 2017, 08:39 ET Worldwide Introduces Latest Additions to its Webinar Series, to Commemorate Heart Month and Rare Disease Day

Worldwide Clinical Trials (http://www.worldwide.com) has announced the latest additions to its free webinar series, both taking place in February....


Feb 09, 2017, 08:30 ET Afatinib to be evaluated in combination with PD-1 inhibitor pembrolizumab in new trial for patients with squamous cell carcinoma of the lung

Boehringer Ingelheim today announced the initiation of a Phase II trial of afatinib (Gilotrif®) in combination with pembrolizumab (Keytruda®) for...


Feb 09, 2017, 08:00 ET Armetheon Reaches Agreement with FDA to Conduct a 1000 Patient Single Phase 3 Study Prior to NDA Filing for its Novel Oral Anticoagulant Tecarfarin

Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced it has...


Feb 09, 2017, 08:00 ET miRNA Modulators of Transcription Factor Targets: Potential Treatments for Hemoglobinopathies

An article published in Experimental Biology and Medicine (Volume 242, Issue 3, February, 2017) identifies microRNAs (miRNAs) as key factors in...


Feb 09, 2017, 07:03 ET Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia)

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...


Feb 09, 2017, 07:00 ET EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity

EnteroMedics Inc. (NASDAQ:ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other...


Feb 08, 2017, 19:22 ET Amgen anuncia que evolocumab disminuyó significativamente el riesgo de eventos cardiovasculares en el estudio FOURIER

Amgen (NASDAQ: AMGN) anunció que el estudio FOURIER, en el que se evaluó la eficacia de evolocumab para reducir el riesgo de eventos...


Feb 08, 2017, 17:04 ET New Study Probes Stakeholder Attitudes on Ethics and Fairness of Cost-Sharing To Steer Appropriate Medication Use

Patients who have the same condition sometimes pay different out-of-pocket costs for their medications, but when is this differential fair? Payers,...


Feb 08, 2017, 16:05 ET Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Study Evaluating JZP-110 for Excessive Sleepiness in Parkinson's Disease

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a...


Feb 08, 2017, 16:03 ET Sangamo Therapeutics Announces Upcoming Presentations At The 13th Annual WORLDSymposium™ Meeting

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the leader in therapeutic genome editing, today announced upcoming oral and poster presentations at the...


Feb 08, 2017, 16:00 ET Neuraltus Pharmaceuticals Provides Enrollment Update on Confirmatory Phase 2 Study of NP001 in ALS

Neuraltus Pharmaceuticals announced the confirmatory Phase 2 study of the Company's lead investigational treatment NP001 for amyotrophic lateral...


Feb 08, 2017, 15:23 ET Phase 3 COMPASS Study of XARELTO® (rivaroxaban) Stopping Early for Efficacy; Study Meets Primary Endpoint of Prevention of Major Adverse Cardiac Events in Patients with Coronary Artery Disease or Peripheral Artery Disease

Janssen Research & Development, LLC (Janssen) today announced that the Phase 3 COMPASS trial, evaluating the efficacy and safety of XARELTO®...


Feb 08, 2017, 08:30 ET MeiraGTx Provides Clinical Trial Updates for Achromatopsia and Leber's Congenital Amaurosis Ocular Gene Therapy Programs

MeiraGTx, a New York and London based gene therapy company, announced today the first patient in its clinical study for achromatopsia due to...


Feb 08, 2017, 08:30 ET Spotlight Innovation Engages Top-Tier Contract Research Organization to Conduct Preclinical Studies of STL-182

Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that it has...